Evidence-based dry-eye therapies for clinical use
8 October 2021
Volume 22, Issue 3
This article outlines a range of dry-eye disease management strategies available at each severity level and between subtypes of the disease.
Domains covered
Professionalism
Clinical practice
Specialty CPD (IP)
Despite recent advances in the management and treatment of dry-eye disease, the condition is still managed differently across continents and countries. From diagnosis to disease progression and treatment, patients should be well informed about the safe and effective use of available therapies. Consequently, this article aims to appraise eye care practitioners of a wide range of management strategies available at each severity level and between subtypes of dry-eye disease.
Sign in to view the article
Not a member? Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
Related further reading
In the first of a three-part series, Helen Bird explores the importance of biomarkers in indicating disease, some of the latest OCT imaging biomarkers and how they relate to optometrists’ work.
About 25,000 people in the UK are diagnosed with NF1, yet many have never heard of the condition. It has ocular signs and symptoms, so what do optometrists need to know?
Mr Kam Balaggan will provide optometrists with an in-depth overview of vitreomacular conditions commonly encountered in everyday practice.Â